Trump Administration Expected to Ease Psychedelic Research Restrictions
The Trump administration is preparing an executive order to expand research into psychedelic drugs including ibogaine for mental health treatment, sources told CBS News. The move would open doors for increased study of these substances.
New Push for Psychedelic Medicine Research
The Trump administration is poised to significantly expand research into psychedelic drugs for mental health treatment through an upcoming executive order, according to CBS News sources.
Expected Policy Changes:
- Ibogaine research expansion for addiction treatment
- Broader access to study previously restricted substances
- Focus on mental health applications for veterans and civilians
- Collaboration between federal agencies and research institutions
Medical Potential
Current Research Interest:
- PTSD treatment for military veterans
- Depression and anxiety disorder applications
- Addiction recovery programs
- End-of-life psychological care
Policy Context
This represents a significant shift in federal drug policy, moving from prohibition toward evidence-based research. The order would complement existing FDA breakthrough therapy designations for certain psychedelic treatments.
Previous Barriers:
- Schedule I drug classifications
- Limited research permits
- Restricted access to substances for studies
- Complex regulatory approval processes
Expert Reception
Former Trump Surgeon General Dr. Jerome Adams described potential appointees in this area as "home run picks," suggesting broad medical community support for expanded psychedelic research.